Gastrointestinal effects remain the most common adverse reactions during maintenance therapy, though typically less severe than during dose escalation
Similarly, the FDA has approved a number of injectable GLP-1s for type 2 diabetes, such as Ozempic (semaglutide), Mounjaro (tirzepatide), and (semaglutide), an oral GLP-1 medication for blood sugar control in people with type 2 diabetes
Bike fueling The bike offers the most comfortable fueling window
Additionally, you should receive ongoing access to a medical team for questions and dose adjustments throughout your journey
Research from peptide discontinuation studies in lipodystrophy populations (the original FDA-approved use case for tesamorelin) showed that visceral adipose tissue began to reaccumulate within 812 weeks after stopping, with the rate of regain correlating inversely to baseline metabolic health
2011;141:216675 e7